IDXX · 8-K · 20261102PR120892

Market Demand Trends

IDEXX LABORATORIES INC /DE · 2026-11-02 · Importance 42 · Surprise 40 · No source text

CAG Diagnostics recurring revenue grew 11% reported and organic, supported by strong same-store volume, net customer gains, and expansion of the premium instrument installed base. IDEXX VetLab consumables revenue increased 14% reported and 15% organic, a $55.4 million increase, with utilization gains and net price benefits. Reference laboratory diagnostic and consulting services grew 10% reported and 10.2% organic, adding $36.4 million, on testing-volume growth, new customer gains, and price realization. Rapid assay revenue increased just 1%, as net price benefits offset lower testing volumes.

Key facts

• IDEXX's third-quarter 2026 revenue was $1,214 million, up 10% as reported and organically, driven by CAG growth of 10% as reported and organically. source
• IDEXX's third-quarter 2026 diluted EPS was $4.01, up 18% as reported and 22% on a comparable basis. source
• IDEXX VetLab consumables revenue grew 14% reported and 15% organically in Q3 2026, supported in part by 11% expansion of the global premium instrument installed base. source
• IDEXX reference laboratory diagnostic and consulting services revenue grew 10% reported and organically in Q3 2026. source
• IDEXX gross profit increased 12% as reported and on a comparable basis in Q3 2026; gross margin was 62.9%, up 110 basis points reported and 90 basis points comparable. source
• IDEXX's Q3 2026 operating margin was 33.1%, up 100 basis points as reported and 60 basis points on a comparable basis; operating expenses increased 10% reported and 11% comparable. source
• IDEXX rapid assay products revenue increased 1% as reported and organically in Q3 2026, with net price benefits offsetting lower testing volumes. source

Impact estimates